This is a duplicate of my Dry Eye Digest blogspot blog - to see the full archives back to 2005, please click on that link.
I guess it's nice to have some hopeful reports like this to round out some of the less impressive results I've been hearing from some of the patients. What we'll all think of it 3 years down the road is anyone's guess at this point.
Case Report: A Successful LipiFlow Treatment of a Single Case of Meibomian Gland Dysfunction and Dropout.
The aim of this study was to investigate whether a single case of meibomian gland dysfunction (MGD), with significant
A Single LipiFlow(®) Thermal Pulsation System Treatment Improves Meibomian Gland Function and Reduces Dry Eye Symptoms for 9 Months.
Purpose: To evaluate the effect of a single treatment with the LipiFlow(®) Thermal Pulsation System on signs of meibomian gland dysfunction (MGD) and dry eye symptoms over a 9-month period. Methods: Patients (n = 42 eyes, 21 subjects) diagnosed with MGD and dry eye symptoms were recruited for a non-significant risk, prospective, open-label,
Interesting article from last month mentions a few practical items that interested dry eye patients might want to know...
How TearScience’s dry eye treatment sparked a new FDA 510(k) strategy
MedCity, 7th Feb 2012
One piece of the commercialization puzzle that TearScience has yet to solve is reimbursement. Insurers do not yet pay for LipiFlow treatment and though the company has applied to instate reimbursement, Willis estimates the entire process can take anywhere
...on February 1st. Yikes, I'm behinder than I thought I was. Sorry about that.
A novel thermodynamic treatment for meibomian gland dysfunction.
To evaluate a novel thermodynamic treatment for obstructive meibomian gland dysfunction (MGD).
Materials and Methods:
Fourteen adult subjects (10 females, 4 males, mean age = 54.2 ± 9.6 yr) were recruited in a multi-center, feasibility clinical trial in Durham and Cary, North Carolina and Boston, Massachusetts. Inclusion criteria included: previous diagnosis of moderate